CY1114714T1 - USE OF DIFFERIPRON AND METHODS FOR THE TREATMENT AND / OR PREVENTION OF FRIEDREICH DISTRIBUTION Caused by Intracellular Iron Management - Google Patents
USE OF DIFFERIPRON AND METHODS FOR THE TREATMENT AND / OR PREVENTION OF FRIEDREICH DISTRIBUTION Caused by Intracellular Iron ManagementInfo
- Publication number
- CY1114714T1 CY1114714T1 CY20131101106T CY131101106T CY1114714T1 CY 1114714 T1 CY1114714 T1 CY 1114714T1 CY 20131101106 T CY20131101106 T CY 20131101106T CY 131101106 T CY131101106 T CY 131101106T CY 1114714 T1 CY1114714 T1 CY 1114714T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- prevention
- differipron
- friedreich
- iron
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Μία θεραπευτικά αποτελεσματική ποσότητα δεφεριπρόνης ή δεφερασιρόξ ή φυσιολογικά αποδεκτών αλάτων αυτών για την πρόληψη, σταθεροποίηση, θεραπεία ή αντιστροφή της προκαλούμενης από σίδηρο FRDA ασθένειας σε ασθενείς που προκύπτει από βλάβη που προκαλείται στα μιτοχόνδρια από σίδηρο για να ελαττώσει κατά προτίμηση τα αποθηκεύματα σιδήρου στα μιτοχόνδρια. Επίσης για την θεραπεία άλλων καταστάσεων που επηρεάζουν τον εγκέφαλο όπου το στοιχείο κλειδί για την δημιουργία της προκύπτουσας παθολογίας είναι ενδοκυτταρική κακή διαχείριση σιδήρου.A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment or reversal of iron-induced FRDA disease in patients resulting from damage caused by iron mitochondria to reduced iron. Also for the treatment of other conditions affecting the brain where the key element in the creation of the resulting pathology is intracellular iron mismanagement.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77532006A | 2006-02-22 | 2006-02-22 | |
EP07701800.0A EP1991225B1 (en) | 2006-02-22 | 2007-02-21 | The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114714T1 true CY1114714T1 (en) | 2016-10-05 |
Family
ID=58448786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131101106T CY1114714T1 (en) | 2006-02-22 | 2013-12-09 | USE OF DIFFERIPRON AND METHODS FOR THE TREATMENT AND / OR PREVENTION OF FRIEDREICH DISTRIBUTION Caused by Intracellular Iron Management |
Country Status (1)
Country | Link |
---|---|
CY (1) | CY1114714T1 (en) |
-
2013
- 2013-12-09 CY CY20131101106T patent/CY1114714T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY151412A (en) | The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron | |
CY1124489T1 (en) | HPK1 INHIBITORS AND METHODS OF USING THEREOF | |
CY1119939T1 (en) | 2,3-Dihydro-Benzo [1,4] Oxazine Derivative and Related Compounds such as Phosphoinositin-3-Kinase (R3K) Inhibitors for Therapeutic Therapy | |
CY1117776T1 (en) | SPIRIT-OXIDOLI COMPOUNDS ANTIOMETER AND THEIR USES AS A THERAPEUTIC AGENT | |
EA201991697A1 (en) | SULFOXYMINE Glycosidase Inhibitors | |
CY1116333T1 (en) | FUZZOURANI PRODUCERS AS FXR REGULATORY PARTS | |
EA201791981A1 (en) | DERIVATIVES 4- (P-HINONIL) -2-HYDROXYBUTANAMIDE FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | |
CY1108276T1 (en) | COMPOUNDS THAT INFLUENCE Glycokinase | |
CY1124022T1 (en) | DISTRIBUTION SCHEME FOR NITROCATECHOLS | |
CY1123216T1 (en) | GLS1 INHIBITORS FOR THE TREATMENT OF DISEASE | |
CY1123914T1 (en) | TREATMENT OF RAISED LEVELS OF EOSINOPHILS AND/OR BASEOPHILS | |
CR20150589A (en) | BIHETEROARILO COMPOUNDS AND USES OF THE SAME | |
EA201391017A1 (en) | METHODS AND READY MEDICATION FORMS FOR THE TREATMENT OF ALZHEYMER | |
CY1113450T1 (en) | DIAMINOPYRIMIDINES AS P2X3 AND P2X2 / 3 COMPONENTS | |
ECSP13012611A (en) | PIRAZOL-AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2 | |
CY1120163T1 (en) | METHODS OF ADMINISTRATION AND EVALUATION OF NITROGEN SCANNING MEDICINES FOR THE USEFUL HEALTH CARE TREATMENT | |
EA201690212A8 (en) | METHODS OF TREATMENT OR PREVENTION OF OPHTHALMIC PATHOLOGICAL CONDITIONS | |
CY1114140T1 (en) | 4-PYRIDINONE COMPONENTS AND THEIR USE FOR CANCER | |
ATE412636T1 (en) | PIPERAZINYLPYRIDINE DERIVATIVES AS AN AGAINST OBESITY | |
AR088813A1 (en) | METHOD FOR QUANTIFYING CANCER TREATMENT | |
DK3749308T3 (en) | TREATMENT OF PATIENTS WITH CLASSIC FABRY'S DISEASE WITH MIGALASTAT | |
CY1106026T1 (en) | ARYLSULFONAMIDES AS SEPOTONIN ANTAGONISTS FOR THE TREATMENT OF OBESITY | |
CY1116938T1 (en) | HUNTINGTON AND OTHER POLYGLUTAMINE DISEASE REFUNDS | |
EA201071422A1 (en) | METHODS OF TREATING DISEASES ASSOCIATED WITH MEIOTIC KINESIN | |
ES2540151A1 (en) | Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use (Machine-translation by Google Translate, not legally binding) |